Blockchain Registration Transaction Record

NanoViricides Provides Update on Measles Drug Development Program with Potential Antiviral Candidate NV-387

NanoViricides provides update on Measles drug development program emphasizing potential of antiviral candidate NV-387. With promising results against RSV, the company's efforts in developing effective antiviral treatments against measles and other respiratory infections are crucial for public health.

This news matters as it addresses the pressing need for effective antiviral treatments against measles, especially with declining vaccination rates. The development of NV-387 shows promise in combating not only measles but also other respiratory viral infections, including COVID-19, highlighting its potential impact on public health.